Table 1.
Systematic Reviews of Adherence to Adjuvant Endocrine Therapy
| Tamoxifen | Aromatase inhibitor | |
|---|---|---|
| Adherence (range)1,2 | 41% to 88% | 52% to 91% |
| Therapy discontinuation (range)1 | 15% to 20% within year 1 | 5% to 25% within 2 years |
| 5 year therapy discontinuation from meta-regression analysis2 | 47.2% (95% CI, 41.1% to 53.5%)0 | 31.0% (95% CI, 25.9 % to 37.5%) |
1
Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Research Treat 2012; 134 (2): 459–78.
2
Huiart L, Ferdynus C, Giorgi R. A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: a summarizing the data for clinicians. Breast Cancer Res Treat 2013 Feb 3 [Epub ahead of print].